Physician profile
Ivan Martinez
NPI 1265019392
$1,618.93
in general payments reported to CMS, 2019-2025
20 companies · $1,301 in 2025
The $1,301 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $318 · 2025: $1,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,618.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $217.46 | 2025 | Omnipod, Omnipod |
| Antares Pharma, INC. | $211.39 | 2024-2025 | Xyosted |
| Corcept Therapeutics | $197.61 | 2025 | Korlym |
| Abbvie INC. | $193.09 | 2024-2025 | |
| Ibsa Pharma INC. | $131.09 | 2024 | Tirosint, Licart |
| Mannkind Corporation | $95.08 | 2024-2025 | |
| Verity Pharmaceuticals INC. | $79.52 | 2024-2025 | Tlando |
| Novo Nordisk INC | $71.20 | 2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $63.47 | 2025 | |
| Lilly USA, LLC | $55.02 | 2024-2025 | Jardiance, Mounjaro |
| Tolmar, INC. | $53.98 | 2025 | Jatenzo |
| Dexcom, INC. | $47.93 | 2025 | Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $39.06 | 2025 | Yorvipath |
| Electromed, INC. | $38.98 | 2025 | Smartvest |
| Madrigal Pharmaceuticals | $30.09 | 2025 | Rezdiffra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $26.58 | 2025 | Repatha |
| Medtronic, INC. | $21.23 | 2025 | Inpen Smart Insulin Delivery System |
| Acella Pharmaceuticals, LLC | $17.27 | 2025 | NP Thyroid 60 |
| Recordati_rare_diseases_inc. | $14.70 | 2025 | Isturisa |
| Exact Sciences Corporation | $14.18 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.